Top

Osteoporosis International

Published in:

01-04-2013 | Original Article

The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study

Authors: L-A. Fraser, W. D. Leslie, L. E. Targownik, A. Papaioannou, J. D. Adachi, CaMos Research Group

Published in: Osteoporosis International | Issue 4/2013

Abstract

Summary

A large Canadian cohort was studied over 10 years to see if proton pump inhibitor (PPI) use increased the risk of sustaining a fragility fracture. We found an increased risk of fracture in individuals who used PPIs. The risk remained after controlling for other known fracture risk factors.

Introduction

Multiple retrospective studies have linked proton pump inhibitor use with increased risk of fragility fracture. We prospectively studied the association between PPI use and fracture in a large cohort over a 10-year period while controlling for known fracture risk factors.

Methods

We studied 9,423 participants in the Canadian Multicenter Osteoporosis Study. The cohort was formed in 1995–1997 and followed for 10 years with monitoring for incident nontraumatic fracture and PPI use. Cox regression analyses were used to assess the association between PPI use and incident fracture risk.

Results

PPI use, coded as a time-dependent variable, was associated with a shorter time to first nontraumatic fracture, hazard ratio (HR) = 1.75 (95 % confidence interval (CI) 1.41–2.17, p < 0.001). After controlling for multiple risk factors, including femoral neck bone density, the association remained significant, HR = 1.40 (95 % CI 1.11–1.77, p = 0.004). Similar results were obtained after controlling for bisphosphonate use, using PPI “ever” use, or when the outcome was restricted to hip fracture.

Conclusions

In this large prospective population-based cohort study, we found an association between PPI use and increased risk of fragility fracture. Although the increased risk found was modest, this finding is important, given the high prevalence of PPI use and the excess morbidity and mortality associated with osteoporosis-related fractures.

Berger C, Goltzman D, Langsetmo L, Joseph L, Kreiger N, Tenenhouse A et al (2010) Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res 25:1948–1957PubMedCrossRef

Papaioannou A, Kennedy CC, Ioannidis G, Sawka A, Hopman WM, Pickard L et al (2009) The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int 20:703–714PubMedCrossRef

Adachi JD, Loannidis G, Berger C, Joseph L, Papaioannou A, Pickard L et al (2001) The influences of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int 12:903–908PubMedCrossRef

Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–521PubMedCrossRef

Becker DJ, Kilgore ML, Morrisey MA (2010) The societal burden of osteoporosis. Curr Rheumatol Rep 12:186–191PubMedCrossRef

Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000PubMedCrossRef

Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson HE, Prior JC et al (2007) Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 167:188–194PubMedCrossRef

Jetté N, Lix LM, Metge CJ, Prior HJ, McChesney J, Leslie WD (2011) Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis. Arch Neurol 68:107–112PubMedCrossRef

Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123:877–884PubMedCrossRef

10.

Yu EW, Bauer SR, Bain PA, Bauer DC (2011) Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 124:519–526PubMedCrossRef

11.

U.S. Food and Drug Administration (2011). FDA Drug Safety Communication. possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. Accessed at http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpateintsandproviders/ucm213206.htm on July 1, 2011.

12.

Heidelbaugh JJ, Goldberg KL, Inadomi JM (2009) Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk. Am J Gastroenterol 104(Suppl 2):27–32CrossRef

13.

Katz MH (2010) Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med 170:747–748PubMedCrossRef

14.

Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M et al (2010) Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 170:784–790PubMedCrossRef

15.

Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R (2010) A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 56:112–116PubMedCrossRef

16.

Lin SL, Chang HM, Liu CP, Chou LP, Chan JW (2011) Clinical evidence of interaction between clopidogrel and proton pump inhibitors. World J Cardiol 3:153–164PubMedCrossRef

17.

Sheen E, Triadafilopoulos G (2011) Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 56:931–950PubMedCrossRef

18.

Kaye JA, Jick H (2008) Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28:951–959PubMedCrossRef

19.

Targownik LE, Leslie WD (2011) The relationship among proton pump inhibitors, bone disease and fracture. Expert Opin Drug Saf 10:901–912PubMedCrossRef

20.

Kreiger N, Tenenhouse A, Joseph L, Mackenzie T, Poliquin S, Brown JP et al (1999) The Canadian Multicentre Osteoporosis Study (CaMos): background, rationale, methods. Can J Aging 18:376–387CrossRef

21.

Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427PubMedCrossRef

22.

Bessette L, Ste-Marie L-G, Jean S, Davison KS, Beaulieu M, Baranci M et al (2008) The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int 19:79–86PubMedCrossRef

23.

Fisher LD, Lin DY (1999) Time-dependent covariates in the cox proportional-hazards regression model. Annu Rev Public Health 20:145–157PubMedCrossRef

24.

Roux C, Briot K, Gossec L, Kolta S, Blenk T, Felsenberg D et al (2009) Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 84:13–19PubMedCrossRef

25.

Roughead EE, McGeechan K, Sayer GP (2004) Bisphosphonate use and subsequent prescription of acid suppressants. Br J Clin Pharmacol 57:813–816PubMedCrossRef

26.

McGowan B, Bennett K, Barry M, Canny M (2008) The utilisation and expenditure of medicines for the prophylaxis and treatment of osteoporosis. Ir Med J 101:38–41PubMed

27.

Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt BJ, Leufkens HG et al (2011) Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 22(3):903–10PubMedCrossRef

28.

Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–2953PubMedCrossRef

29.

Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179:319–326PubMed

30.

Ensrud KE, Duong T, Cauley JA, Heaney RP, Wolf RL, Harris E et al (2000) Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Ann Intern Med 132:345–353PubMed

31.

Bo-Linn GW, Davis GR, Buddrus DJ, Morawski SG, Santa Ana C, Fordtran JS (1984) An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest 73:640–647PubMedCrossRef

32.

Serfaty-Lacrosniere C, Wood RJ, Voytko D, Saltzman JR, Pedrosa M, Sepe TE et al (1995) Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 14:364–368PubMed

33.

Recker RR (1985) Calcium absorption and achlorhydria. N Engl J Med 313:70–73PubMedCrossRef

34.

O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118:778–781PubMedCrossRef

35.

McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE et al (2004) Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 350:2042–2049PubMedCrossRef

36.

Targownik LE, Lix LM, Leung S, Leslie WD (2010) Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138:896–904PubMedCrossRef

37.

Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E et al (2008) Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 83:251–259PubMedCrossRef

38.

Gray SL, LaCroix AZ, Larson J (2010) Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med 170:765–771PubMedCrossRef

39.

Targownik LE, Leslie WD, Davison S, Goltzmen D, Jamal S, Josse RG, et al Proton pump inhibitors are associated with decreased bone mineral density. Amer J Gastroenterol. 106(Suppl 2):405.

40.

Mizunashi K, Furukawa Y, Katano K, Abe K (1993) Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 53:21–25PubMedCrossRef

41.

Sheraly AR, Lickorish D, Sarraf F, Davies JE (2009) Use of gastrointestinal proton pump inhibitors to regulate osteoclast-mediated resorption of calcium phosphate cements in vivo. Curr Drug Deliv 6:192–198PubMedCrossRef

Title: The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study
Authors: L-A. Fraser
W. D. Leslie
L. E. Targownik
A. Papaioannou
J. D. Adachi
CaMos Research Group
Publication date: 01-04-2013
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 4/2013
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-012-2112-9

At a glance: The STEP trials

Springer Medicine

The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2013

The assessment of vertebral fractures in elderly women with recent hip fractures: the BREAK Study

Prognostic value of cardiac troponins in elderly patients with hip fracture—a systematic review

The relationship between obesity and the increase in serum 25(OH)D levels in response to vitamin D supplementation

Erratum to: Impact of nutrition on muscle mass, strength, and performance in older adults

Risk factors affecting progressive collapse of acute osteoporotic spinal fractures

Bilateral ulna fractures associated with bisphosphonate therapy